<unk>  Converting Enzyme (ACE)<unk>  remains first line therapy among STEMI patients, particularly those with poor left ventricular function following ST<unk><unk><unk> . The benefits of ACE<unk>  are clear among patients with an anterior<unk><unk>  and are less clear among patients with non-anterior<unk><unk> .  Patients who cannot tolerate an ACE inhibitor (for example they develop a cough) can be treated with an<unk>  Receptor Blocker (ARB).  In addition to an ACE inhibitor, if a patient has symptomatic heart failure or a left ventricular ejection fraction < 40% and does not have impaired renal function or hyperkalemia, then long-term<unk>  blockade should be administered.
ST elevation myocardial infarction inhibition of the renin-angiotensin-aldosterone system at discharge
Chronic stable angina patient follow-up
ST elevation myocardial infarction calcium channel blocker therapy
Chronic stable angina echocardiography
Unstable angina / non ST elevation myocardial infarction blood studies
Chronic stable angina exercise echocardiography
Chronic stable angina ambulatory ST segment monitoring
Stress cardiomyopathy echocardiography or ultrasound